[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)].

Abstract

We evaluated the efficacy and safety of the epirubicin plus docetaxel(ET)regimen, which is a combination of active agents given to patients with inflammatory breast cancer(IBC)as a primary therapy. Nineteen patients received ET(60, 60mg/m2) every 3 weeks for 4 courses, and appropriate surgery was offered unless disease progression occurred. Seventeen patients completed the ET regimen and 1 patient was excluded because of no diffuse erythema, leaving 18 patients evaluable for the response and safety profile of this regimen. Grade 3/4 hematological toxicities were neutropenia in 15 patients(79%), febrile neutropenia in 8 patients(42%)and anemia in 3 patients(16%). Six patients(63%)received granulocyte colony-stimulating factor for febrile neutropenia. Febrile neutropenia was observed only for 1 course in all 6 patients and progression to apparent infection was not observed. Grade 3/4 non-hematological toxicities were constipation in 3, nausea in 2, anorexia in 2, fatigue in 1, vomiting in 1, diarrhea in 1, and stomatitis in 1 patient. The ET regimen was given to 16 patients(89%)as planned. The median number of courses was 4(range: 2-4). The clinical response rate was 44%. The median time to progression was 9 months, and median overall survival was 26 months. It is concluded that the ET regimen was well tolerated and effective as a primary chemotherapy for IBC.

• Authors: Michiyo Saimura, Keisei Anan, Shoshu Mitsuyama, Satoshi Toyoshima, Koji Ikejiri, Tetsufumi Ohchi, Yoshiaki Rai, Tatsuji Oikawa, Manabu Kudaka, Reiki Nishimura, Shoji Kuroki, Kiyoshi Namba, Yuji Nakafusa, Kazuo Tamura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 7 Pg. 1075-9 (Jul 2012) ISSN: 0385-0684 [Print] Japan
• PMID: 22790042 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Taxoids
• Docetaxel
• Epirubicin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Combined Modality Therapy
• Docetaxel
• Epirubicin (administration & dosage, adverse effects)
• Female
• Humans
• Inflammatory Breast Neoplasms (drug therapy, surgery)
• Middle Aged
• Taxoids (administration & dosage, adverse effects)